Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet

Comment

Bridget F Koontz. Int J Radiat Oncol Biol Phys. 2017.

. 2017 Nov 15;99(4):761-763.

doi: 10.1016/j.ijrobp.2017.05.020.

No abstract available

Comment on

Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis.
Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G. Ost P, et al. Eur Urol. 2016 Jan;69(1):9-12. doi: 10.1016/j.eururo.2015.07.004. Epub 2015 Jul 16. Eur Urol. 2016. PMID: 26189689
(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T. Henkenberens C, et al. Strahlenther Onkol. 2016 Jul;192(7):431-9. doi: 10.1007/s00066-016-0982-z. Epub 2016 Jun 7. Strahlenther Onkol. 2016. PMID: 27272755 Clinical Trial. English.
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS, Matthews JH, Atkinson C, Tai KH, Duchesne G, Christie D, Attia J, Holliday EG, Denham JW. Sridharan S, et al. Radiother Oncol. 2016 Oct;121(1):98-102. doi: 10.1016/j.radonc.2016.07.021. Epub 2016 Aug 12. Radiother Oncol. 2016. PMID: 27528117 Clinical Trial.